One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
In The Literature
doi : 10.1093/cid/ciac017
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages i–ii,
The Effect of Neutropenia and Filgrastim (G-CSF) on Cancer Patients With Coronavirus Disease 2019 (COVID-19) Infection
Allen W Zhang, Sejal Morjaria, Anna Kaltsas, Tobias M Hohl, Rekha Parameswaran, Dhruvkumar Patel, Wei Zhou, Jacqueline Predmore, Rocio Perez-Johnston, Justin Jee, Anthony F Daniyan, Miguel-Angel Perales, Ying Taur
doi : 10.1093/cid/ciab534
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 567–574
Neutropenia is commonly encountered in cancer patients. Recombinant human granulocyte colony-stimulating factor (G-CSF, filgrastim), a cytokine that initiates proliferation and differentiation of mature granulocytes, is widely given to oncology patients to counteract neutropenia, reducing susceptibility to infection. However, the clinical impact of neutropenia and G-CSF use in cancer patients with coronavirus disease 2019 (COVID-19) remains unknown.
The Impact of Current Opioid Agonist Therapy on Hepatitis C Virus Treatment Initiation Among People Who Use Drugs From the Direct-acting Antiviral (DAA) Era: A Population-Based Study
Sofia R Bartlett, Stanley Wong, Amanda Yu, Margo Pearce, Julia MacIsaac, Susan Nouch, Prince Adu, James Wilton, Hasina Samji, Emilia Clementi, Hector Velasquez, Dahn Jeong, Mawuena Binka, Maria Alvarez, Jason Wong, Jane Buxton, Mel Krajden, Naveed Z Janjua
doi : 10.1093/cid/ciab546
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 575–583
Evidence that opioid agonist therapy (OAT) is associated with increased odds of hepatitis C virus (HCV) treatment initiation among people who use drugs (PWUD) is emerging. The objective of this study was to determine the association between current OAT and HCV treatment initiation among PWUD in a population-level linked administrative dataset.
Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in All of Us Research Program Participants, 2 January to 18 March 2020
Keri N Althoff, David J Schlueter, Hoda Anton-Culver, James Cherry, Joshua C Denny, Isaac Thomsen, Elizabeth W Karlson, Fiona P Havers, Mine S Cicek, Stephen N Thibodeau, Ligia A Pinto, Douglas Lowy, Bradley A Malin, Lucila Ohno-Machado, Carolyn Williams, David Goldstein, Aymone Kouame, Andrea Ramirez, Adrienne Roman, Norman E Sharpless, Kelly A Gebo, Sheri D Schully
doi : 10.1093/cid/ciab519
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 584–590
With limited severe acute respiratory syndrome coronavirus (SARS-CoV-2) testing capacity in the United States at the start of the epidemic (January–March 2020), testing was focused on symptomatic patients with a travel history throughout February, obscuring the picture of SARS-CoV-2 seeding and community transmission. We sought to identify individuals with SARS-CoV-2 antibodies in the early weeks of the US epidemic.
Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees
Mark A Jacobson, Adam Zakaria, Zaw Maung, Colin Hart, Timothy H McCalmont, Marlys Fassett, Erin Amerson
doi : 10.1093/cid/ciab518
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 591–596
mRNA SARS-CoV-2 vaccines are administered to 2 million individuals per day in the United States under US Food and Drug Administration emergency use authorization.
Mathematical Modeling to Inform Vaccination Strategies and Testing Approaches for Coronavirus Disease 2019 (COVID-19) in Nursing Homes
Rebecca Kahn, Inga Holmdahl, Sujan Reddy, John Jernigan, Michael J Mina, Rachel B Slayton
doi : 10.1093/cid/ciab517
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 597–603
Nursing home residents and staff were included in the first phase of coronavirus disease 2019 vaccination in the United States. Because the primary trial endpoint was vaccine efficacy (VE) against symptomatic disease, there are limited data on the extent to which vaccines protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the ability to infect others (infectiousness).
Pediatric Staphylococcus aureus Bacteremia: Clinical Spectrum and Predictors of Poor Outcome
Anita J Campbell, Laila S Al Yazidi, Linny K Phuong, Clare Leung, Emma J Best, Rachel H Webb, Lesley Voss, Eugene Athan, Philip N Britton, Penelope A Bryant, Coen T Butters, Jonathan R Carapetis, Natasha S Ching, Geoffrey W Coombs, Denise A Daley, Joshua R Francis, Te-Yu Hung, Shakeel Mowlaboccus, Clare Nourse, Samar Ojaimi, Alex Tai, Nan Vasilunas, Brendan McMullan, Christopher C Blyth, Asha C Bowen
doi : 10.1093/cid/ciab510
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 604–613
Staphylococcus aureus is a common cause of bacteremia, yet the epidemiology and predictors of poor outcome remain inadequately defined in childhood.
Prolonged Suppression of Butyrate-Producing Bacteria Is Associated With Acute Gastrointestinal Graft-vs-Host Disease and Transplantation-Related Mortality After Allogeneic Stem Cell Transplantation
Elisabeth Meedt, Andreas Hiergeist, André Gessner, Katja Dettmer, Gerhard Liebisch, Sakhila Ghimire, Hendrik Poeck, Matthias Edinger, Daniel Wolff, Wolfgang Herr, Ernst Holler, Daniela Weber
doi : 10.1093/cid/ciab500
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 614–621
Butyrogenic bacteria play an important role in gut microbiome homeostasis and intestinal epithelial integrity. Previous studies have demonstrated an association between administration of short-chain fatty acids like butyrate and protection from acute graft-vs-host disease (GvHD) after allogeneic stem cell transplantation (ASCT).
Risk of Reinfection After Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score Matched Cohort Study
Antonio Leidi, Flora Koegler, Roxane Dumont, Richard Dubos, MarÃa-Eugenia Zaballa, Giovanni Piumatti, Matteo Coen, Amandine Berner, Pauline Darbellay Farhoumand, Pauline Vetter, Nicolas Vuilleumier, Laurent Kaiser, Delphine Courvoisier, Andrew S Azman, Idris Guessous, Silvia Stringhini, SEROCoV-POP study group
doi : 10.1093/cid/ciab495
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 622–629
Serological assays detecting anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies are being widely deployed in studies and clinical practice.
Risk Factors for Death Among the First 80 543 Coronavirus Disease 2019 (COVID-19) Cases in China: Relationships Between Age, Underlying Disease, Case Severity, and Region
Yanping Zhang, Wei Luo, Qun Li, Xijie Wang, Jin Chen, Qinfeng Song, Hong Tu, Ruiqi Ren, Chao Li, Dan Li, Jing Zhao, Jennifer M McGoogan, Duo Shan, Bing Li, Jingxue Zhang, Yanhui Dong, Yu Jin, Shuai Mao, Menbao Qian, Chao Lv, Huihui Zhu, Limin Wang, Lin Xiao, Juan Xu, Dapeng Yin, Lei Zhou, Zhongjie Li, Guoqing Shi, Xiaoping Dong, Xuhua Guan, George F Gao, Zunyou Wu, Zijian Feng
doi : 10.1093/cid/ciab493
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 630–638
Knowledge of COVID-19 epidemiology remains incomplete and crucial questions persist. We aimed to examine risk factors for COVID-19 death.
Genetic and Epidemiologic Analyses of an Outbreak of Pneumocystis jirovecii Pneumonia Among Kidney Transplant Recipients in the United States
Marwan M Azar, Elizabeth Cohen, Liang Ma, Ousmane H Cissé, Geliang Gan, Yanhong Deng, Kristen Belfield, William Asch, Matthew Grant, Shana Gleeson, Alan Koff, David C Gaston, Jeffrey Topal, Shelly Curran, Sanjay Kulkarni, Joseph A Kovacs, Maricar Malinis
doi : 10.1093/cid/ciab474
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 639–647
Pneumocystis jirovecii is an opportunistic fungus that causes Pneumocystis pneumonia (PCP) in immunocompromised hosts. Over an 11-month period, we observed a rise in cases of PCP among kidney-transplant recipients (KTR), prompting an outbreak investigation.
Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile
Nicholas A Turner, Bobby G Warren, Maria F Gergen-Teague, Rachel M Addison, Bechtler Addison, William A Rutala, David J Weber, Daniel J Sexton, Deverick J Anderson
doi : 10.1093/cid/ciab473
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 648–656
Shedding of Clostridioides difficile spores from infected individuals contaminates the hospital environment and contributes to infection transmission. We assessed whether antibiotic selection affects C. difficile shedding and contamination of the hospital environment.
Pneumococcal Meningitis in Adults: A Prospective Nationwide Cohort Study Over a 20-year Period
Diederik L H Koelman, Matthijs C Brouwer, Liora ter Horst, Merijn W Bijlsma, Arie van der Ende, Diederik van de Beek
doi : 10.1093/cid/ciab477
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 657–667
The epidemiology and treatment of pneumococcal meningitis has changed with the implementation of conjugate vaccines and the introduction of adjunctive dexamethasone therapy.
Sensitivity, Specificity, and Safety of a Novel ESAT6-CFP10 Skin Test for Tuberculosis Infection in China: 2 Randomized, Self-Controlled, Parallel-Group Phase 2b Trials
Miao Xu, Wei Lu, Tao Li, Jingxin Li, Weixin Du, Qi Wu, Qiao Liu, Baodong Yuan, Jinbiao Lu, Xiaoyan Ding, Feng Li, Min Liu, Baowen Chen, Jiang Pu, Rongping Zhang, Xiuhong Xi, Rongguang Zhou, Zaoxian Mei, Ronghui Du, Lifeng Tao, Leonardo Martinez, Shuihua Lu, Guozhi Wang, Fengcai Zhu
doi : 10.1093/cid/ciab472
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 668–677
Diagnostics to identify tuberculosis infection are limited. We aimed to assess the diagnostic accuracy and safety of ESAT6-CFP10 (EC) skin test for tuberculosis infection in Chinese adults.
Subclinical Tuberculosis in Children: Diagnostic Strategies for Identification Reported in a 6-year National Prospective Surveillance Study
Nora Fritschi, Ante Wind, Jürg Hammer, Nicole Ritz
doi : 10.1093/cid/ciab708
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 678–684
Subclinical tuberculosis (TB) is well recognized and defined as a disease state with absent or nonrecognized symptoms. The study identifies factors associated with subclinical TB and diagnostic strategies in a low-burden, high-resource country.
Serial Intervals and Case Isolation Delays for Coronavirus Disease 2019: A Systematic Review and Meta-Analysis
Sheikh Taslim Ali, Amy Yeung, Songwei Shan, Lin Wang, Huizhi Gao, Zhanwei Du, Xiao-Ke Xu, Peng Wu, Eric H Y Lau, Benjamin J Cowling
doi : 10.1093/cid/ciab491
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 685–694
Estimates of the serial interval distribution contribute to our understanding of the transmission dynamics of coronavirus disease 2019 (COVID-19). Here, we aimed to summarize the existing evidence on serial interval distributions and delays in case isolation for COVID-19.
Transmission of Antimicrobial Resistant Yersinia pestis During a Pneumonic Plague Outbreak
Voahangy Andrianaivoarimanana, David M Wagner, Dawn N Birdsell, Birgit Nikolay, Faniry Rakotoarimanana, Lovasoa N Randriantseheno, Amy J Vogler, Jason W Sahl, Carina M Hall, Nawarat Somprasong, Simon Cauchemez, Herbert P Schweizer, Harimahefa Razafimandimby, Christophe Rogier, Minoarisoa Rajerison
doi : 10.1093/cid/ciab606
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 695–702
Pneumonic plague (PP), caused by Yersinia pestis, is the most feared clinical form of plague due to its rapid lethality and potential to cause outbreaks. PP outbreaks are now rare due to antimicrobial therapy.
Increased Household Secondary Attacks Rates With Variant of Concern Severe Acute Respiratory Syndrome Coronavirus 2 Index Cases
Sarah A Buchan, Semra Tibebu, Nick Daneman, Michael Whelan, Thuva Vanniyasingam, Michelle Murti, Kevin A Brown
doi : 10.1093/cid/ciab496
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 703–706
We compared secondary attack rates in households with B.1.1.7 variant of concern (VOC) versus non-VOC index cases in a matched cohort in Ontario, Canada. The secondary attack rate for VOC index cases was 1.31 times higher than non-VOC index cases. This increase was particularly accentuated for asymptomatic or presymptomatic index cases.
Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers
Stéphane Marot, Isabelle Malet, Valentin Leducq, Basma Abdi, Elisa Teyssou, Cathia Soulie, Marc Wirden, Christophe Rodriguez, Slim Fourati, Jean-Michel Pawlotsky, David Boutolleau, Sonia Burrel, Vincent Calvez, Anne-Geneviève Marcelin, Aude Jary
doi : 10.1093/cid/ciab492
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 707–710
There are concerns about neutralizing antibodies’ (NAbs’) potency against severe acute respiratory syndrome coronavirus 2 variants. Despite decreased NAb titers elicited by BNT162b2 vaccine against VOC202012/01 and 501Y.V2 strains, 28/29 healthcare workers (HCWs) had an NAb titer ≥1:10. In contrast, 6 months after coronavirus disease 2019 mild forms, only 9/15 (60%) of HCWs displayed detectable NAbs against 501Y.V2 strain.
Provider Satisfaction With Infectious Diseases Telemedicine Consults for Hospitalized Patients During the Coronavirus Disease 2019 (COVID-19) Pandemic
Joseph E Canterino, Kaicheng Wang, Marjorie Golden
doi : 10.1093/cid/ciab479
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 711–714
During the coronavirus disease 2019 (COVID-19) pandemic, our institution transitioned infectious diseases (ID) consultations on hospitalized patients to telemedicine.
Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients
Alana F Ogata, Chi-An Cheng, Michaël Desjardins, Yasmeen Senussi, Amy C Sherman, Megan Powell, Lewis Novack, Salena Von, Xiaofang Li, Lindsey R Baden, David R Walt
doi : 10.1093/cid/ciab465
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 715–718
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins were measured in longitudinal plasma samples collected from 13 participants who received two doses of mRNA-1273 vaccine. Eleven of 13 participants showed detectable levels of SARS-CoV-2 protein as early as day 1 after first vaccine injection. Clearance of detectable SARS-CoV-2 protein correlated with production of immunoglobulin G (IgG) and immunoglobulin A (IgA).
Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in a University Student Population
Lior Rennert, Christopher McMahan
doi : 10.1093/cid/ciab454
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 719–722
We assess protection from previous SARS-CoV-2 infection in 16,101 university students. Among 2,021 students previously infected in Fall 2020, risk of re-infection during the Spring 2021 semester was 2.2%; estimated protection from previous SARS-CoV-2 infection was 84% (95% CI: 78%–88%).
Advancing Diagnostic Stewardship for Healthcare-Associated Infections, Antibiotic Resistance, and Sepsis
Emily J Curren, Joseph D Lutgring, Sarah Kabbani, Daniel J Diekema, Steven Gitterman, Ebbing Lautenbach, Daniel J Morgan, Clare Rock, Reynolds M Salerno, L Clifford McDonald
doi : 10.1093/cid/ciab672
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 723–728
Diagnostic stewardship means ordering the right tests for the right patient at the right time to inform optimal clinical care. Diagnostic stewardship is an integral part of antibiotic stewardship efforts to optimize antibiotic use and improve patient outcomes, including reductions in antibiotic resistance and treatment of sepsis.
Leveraging a Preexisting Global Infectious Disease Network for Local Decision Making During a Pandemic
Jocelyn J Herstein, John J Lowe, Timo Wolf, Shawn Vasoo, Yee Sin Leo, Bum Sik Chin, Yinzhong Shen, Angela L Hewlett, James V Lawler
doi : 10.1093/cid/ciab660
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 729–733
Emerging infectious disease epidemics require a rapid response from health systems; however, evidence-based consensus guidelines are generally absent early in the course of events. Formed in 2017 by 5 high-level isolation units spanning 3 continents, the experience of the Global Infectious Disease Preparedness Network (GIDPN) early in the course of coronavirus disease 2019 (COVID-19) provides a model for accelerating best practice development and improving decision-making in health emergencies.
Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis
Xinhua Chen, Zhiyuan Chen, Andrew S Azman, Ruijia Sun, Wanying Lu, Nan Zheng, Jiaxin Zhou, Qianhui Wu, Xiaowei Deng, Zeyao Zhao, Xinghui Chen, Shijia Ge, Juan Yang, Daniel T Leung, Hongjie Yu
doi : 10.1093/cid/ciab646
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 734–742
Recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants may pose a threat to immunity. A systematic landscape of neutralizing antibodies against emerging variants is needed. We systematically searched for studies that evaluated neutralizing antibody titers induced by previous infection or vaccination against SARS-CoV-2 variants and collected individual data. We identified 106 studies meeting the eligibility criteria.
Chronic Cutaneous Lesion on the Left Lower Abdominal Wall
William Stokes, Wilson W Chan, Amy Thommasen, Stephen Vaughan
doi : 10.1093/cid/ciab329
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 743–745
Strong Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody Response of Previously Infected Healthcare Workers Given 1 Dose of mRNA Vaccine
Chloé Dimeglio, Fabrice Herin, Isabelle Da-Silva, Marion Porcheron, Guillaume Martin-Blondel, Marcel Miedougé, Jacques Izopet
doi : 10.1093/cid/ciab573
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Page 746
The Risk of Underestimating the Contribution of Children to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic
Gilles Darcis, Christelle Meuris, Cécile Kremer, Christel Faes, Niel Hens
doi : 10.1093/cid/ciab571
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Page 747
Reply to Darcis et al
Antoni Soriano-Arandes, Aida Perramon, Anna Gatell, Pepe Serrano, Clara Prats, Pere Soler-Palacin
doi : 10.1093/cid/ciab572
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 747–749
Empiric Antibiotics in Hospitalized Pneumonia: Discontinuation Is Better than De-escalation
Mathieu Blot, Aurélien Dinh
doi : 10.1093/cid/ciab544
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 749–750
Reply to Blot and Dinh
Abhishek Deshpande, Michael B Rothberg
doi : 10.1093/cid/ciab545
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 750–751
Adverse Outcomes Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant B.1.351 Infection in Vaccinated Residents of a Long-Term Care Home, Ontario, Canada
Ahmed Vanker, Allison J McGeer, Gray O’Byrne, Ellen C R Snyder, David A Salisbury, Jennifer L Guthrie, Samir N Patel, Jonathan B Gubbay, Matthew Morgan
doi : 10.1093/cid/ciab523
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 751–752
Early Monoclonal Antibody Administration Can Reduce Both Hospitalizations and Mortality in High-Risk Outpatients With Coronavirus Disease 2019 (COVID-19)
Jeffrey D Jenks, Saima Aslam, Lucy E Horton, Nancy Law, Ajay Bharti, Cathy Logan, Mahnaz Taremi, Florin Vaida, Michele Ritter, COVID-19 Clinic Team
doi : 10.1093/cid/ciab522
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 752–753
The Potential Declining Efficacy of the ChAdOx1 nCoV-19 Vaccine (AZD1222) on Inoculators With Nonsteroidal Anti-inflammatory Drug (NSAID) Intake
Hsin-Fu Yeh
doi : 10.1093/cid/ciab516
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages 753–754
Corrigendum to: CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
Rulan Griesel, Gary Maartens, Maxwell Chirehwa, Simiso Sokhela, Godspower Akpomiemie, Michelle Moorhouse, Francois Venter, Phumla Sinxadi
doi : 10.1093/cid/ciab804
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Page 755
Corrigendum to: Clinical Effectiveness of Integrase Strand Transfer Inhibitor–Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada
Haidong Lu, Stephen R Cole, Daniel Westreich, Michael G Hudgens, Adaora A Adimora, Keri N Althoff, Michael J Silverberg, Kate Buchacz, Jun Li, Jessie K Edwards, Peter F Rebeiro, Viviane D Lima, Vincent C Marconi, Timothy R Sterling, Michael A Horberg, M John Gill, Mari M Kitahata, Joseph J Eron, Richard D Moore
doi : 10.1093/cid/ciab799
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Page 755
Erratum to: A Novel Human Acute Encephalitis Caused by Pseudorabies Virus Variant Strain
Qingyun Liu, Xiaojuan Wang, Caihua Xie, Shifang Ding, Hongna Yang, Shibang Guo, Jixuan Li, Lingzhi Qin, Fuguo Ban, Dongfang Wang, Cui Wang, Lingxiao Feng, Haichang Ma, Bin Wu, Liping Zhang, Changxian Dong, Li Xing, Jiewen Zhang, Huanchun Chen, Ruoqian Yan, Xiangru Wang, Wei Li
doi : 10.1093/cid/ciab550
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Page 756
Previous Syphilis Alters the Course of Subsequent Episodes of Syphilis
Christina M Marra, Clare L Maxwell, Sharon K Sahi, Lauren C Tantalo, Shelia B Dunaway, Sheila A Lukehart
doi : 10.1093/cid/ciab287
Clinical Infectious Diseases, Volume 74, Issue 4, 15 February 2022, Pages e1–e5
